课题基金 / 基金详情

表达APOA1的溶瘤腺病毒调节肿瘤炎性微环境的作用及其机制研究

批准号:
82103453
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
曹亚娟
依托单位:
学科分类:
肿瘤微环境
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
曹亚娟

项目摘要

结项摘要

相似基金

相关文献

中文摘要
溶瘤腺病毒具有直接溶瘤及诱导抗肿瘤免疫作用,在临床研究中取得了一定疗效。而病毒诱导的负性炎症免疫和肿瘤炎性环境限制了溶瘤腺病毒的疗效。本课题组前期构建了表达载脂蛋白A1的溶瘤腺病毒(Ad5-APOA1),发现APOA1促进溶瘤病毒复制与扩散、活化CD8+T细胞、抑制部分免疫负性细胞因子、增强溶瘤腺病毒治疗肝癌的疗效。然而APOA1调控肝癌微环境的作用及机理尚不明。前期工作证实Ad5-APOA1显著下调肿瘤细胞和CD8+T细胞内胆固醇水平,其代谢物27-羟固醇(27-HC)在多种肿瘤中均可增强TNFa的促肿瘤作用。因此我们假设,Ad5-APOA1感染肝癌细胞后,分泌APOA1,下调肿瘤及周围细胞内胆固醇和27-HC水平,抑制肿瘤微环境免疫细胞TNF通路活化,抑制免疫负反应,增强溶瘤腺病毒疗效。研究结果将阐明Ad5-APOA1影响肿瘤炎性微环境的具体机制,为日后临床转化提供平台支撑和实践依据。
英文摘要
Due to its direct oncolytic effect and induced anti-tumor immunity, oncolytic adenovirus therapy has achieved certain curative effects in both basic and clinical research. However, the inflammatory environment of the tumor microenvironment itself and the negative regulation of inflammation-related immunity induced by the oncolytic adenovirus itself greatly limit the efficacy of the oncolytic adenovirus. In the previous study, our group constructed an oncolytic adenovirus Ad5-APOA1 that overexpressed apolipoprotein A1(APOA1), and found that it can significantly improve the efficacy of oncolytic adenovirus in liver cancer, and further studies have found that it can significantly inhibit TNF(Tumor necrosis factor, TNF) pathway also activates immunity in CD8+T cell. The mechanism by which apolipoprotein A1 inhibits the TNF pathway is unknown. In vivo and in vitro experiments have found that Ad5-APOA1 can significantly down-regulate cholesterol levels in tumor cells. Cholesterol metabolite 27-hydroxycholesterol(27-hydroxycholesterol, 27-HC) can promote the TNF pathway to promote tumor progression in a variety of tumors. Therefore, we hypothesized that after Ad5-APOA1 infects liver cancer cells, down-regulating the level of cholesterol in the tumor microenvironment inhibits the production of 27-HC, thereby inhibiting the TNF pathway of CD8+ T cells and ultimately improving the efficacy of oncolytic adenovirus. The research results will clarify the specific mechanism of Ad5-APOA1 affecting the inflammatory pathway, and provide platform support and a practical basis for future clinical translational applications.
肝癌是我国常见恶性肿瘤,发病隐匿、预后差,急需有效治疗手段。溶瘤病毒虽有疗效,但受肿瘤炎性微环境等限制。载脂蛋白 A1(APOA1)参与胆固醇代谢,还能抗炎、调节免疫与抗氧化,本课题构建 Ad5-APOA1 旨在提升抗肿瘤效果并探究其分子机制。.研究方法上,先是利用 TCGA、GEO 数据库分析 APOA1 在多种肿瘤中的表达及与预后关系,接着构建 Ad5-APOA1,体外验证其复制、溶瘤能力,还在裸鼠、NCG 人源化小鼠及 Balb/c 小鼠肝癌模型中验证抗肿瘤作用,且在 Balb/c 肝癌模型小鼠中用多种检测方法确定其对肿瘤微环境影响及潜在机制。.研究结果分三部分。其一,泛肿瘤中 APOA1 表达较癌旁组织显著下调,在肝癌中随进展下调,且与肝癌患者预后正相关。Ad5-APOA1 在肝癌细胞系中复制、溶瘤能力更强,对裸鼠肝癌模型无治疗作用,但在健全免疫及人源化免疫重建小鼠肝癌模型中可抑制肝癌生长、延长生存期。其二,Ad5-APOA1 依赖 CD8+T 细胞发挥抑制肝癌疗效,能促进其 IFN-γ 及 GzmB 表达,抑制免疫检查点 PD-1 和 LAG-3 表达。其三,CD8+T 细胞内胆固醇含量与免疫检查点表达相关,APOA1 可促进胆固醇外排、下调肝癌组织胆固醇水平,减少 CD8+T 细胞内胆固醇累积,Ad5-APOA1 还能抑制炎症通路激活。.结论为:Ad5-APOA1 治疗肝癌效果显著,依赖免疫系统;可诱导 CD8+T 细胞免疫活化,抑制免疫检查点;能促进胆固醇外排,抑制炎症及免疫负性调节。
国内基金
海外基金